Mersana Therapeutics Completes Acquisition by Day One Biopharmaceuticals; Shares to Delist

summarizeSummary

Mersana Therapeutics, Inc. announced the completion of its acquisition by Day One Biopharmaceuticals, Inc., following the successful tender offer for its outstanding shares. As a result, Mersana's shares will be delisted from Nasdaq.

check_boxKey Events

• Merger Completed

  Mersana Therapeutics, Inc. has been acquired by Emerald Merger Sub, Inc., a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc., effective January 6, 2026.

• Tender Offer Results

  The tender offer for Mersana's shares expired on January 5, 2026, with 3,029,135 shares, representing approximately 60.57% of outstanding shares, validly tendered and not withdrawn. The minimum condition for the offer was satisfied.

• Consideration Received

  Shareholders who tendered will receive $25.00 per share in cash, plus one non-tradeable contingent value right (CVR) per share, which offers potential milestone payments up to an aggregate of $30.25 per CVR.

• Delisting and Deregistration

  As a result of the merger, Mersana Therapeutics' common stock will be delisted from the Nasdaq Stock Market, and the company will cease its reporting obligations under the Exchange Act.

auto_awesomeAnalysis

The completion of the acquisition by Day One Biopharmaceuticals marks a definitive end to Mersana Therapeutics as an independent public entity. Shareholders who validly tendered their shares will receive the agreed-upon consideration of $25.00 in cash per share plus one contingent value right (CVR) for potential future payments. This event fundamentally alters the investment thesis for Mersana, as its shares will cease trading on Nasdaq and the company will no longer have public reporting obligations. Investors should be aware that their shares will be converted into the merger consideration.